Abstract:One receptor, DDR2, both promotes the differentiation of bone-depositing cells and prevents the differentiation of bone-resorbing cells. Reorganizing receptor complexes to rebuild bone The skeleton undergoes continuous turnover mediated by osteoblasts and osteoclasts, which respectively deposit and resorb bone. When this turnover is dysregulated, skeletal diseases such as osteoporosis—a disease characterized by bone loss—can occur. The receptor tyrosine kinase DDR2 (discoidin domain receptor 2) tilts the balance in favor of bone formation. Zhang et al. determined that, in addition to promoting osteoblast differentiation, DDR2 inhibited osteoclast differentiation and bone matrix resorption in culture. In a mouse model of osteoporosis, viral-mediated delivery of DDR2 increased bone density. By forming a complex with the receptors Neuropilin-1 and PlexinA1, DDR2 blocked PlexinA1-mediated stimulation of osteoclastogenesis. Thus, increasing the abundance of DDR2 in both types of bone precursor cells may be therapeutically beneficial for osteoporosis patients. Osteoporosis is a disease characterized by abnormal skeletal fragility due to an imbalance in bone homeostasis. Finding therapeutic targets that promote bone formation is valuable for treating osteoporosis. Discoidin domain receptor 2 (DDR2) is a receptor tyrosine kinase that promotes the differentiation of bone-depositing cells, osteoblasts, and bone formation. We investigated the role of DDR2 in osteoclastogenesis, the formation of cells responsible for bone resorption. We found that, although differentiated osteoclasts had catalytically active DDR2, its abundance was decreased. Overexpression of DDR2 inhibited the expression of osteoclastic markers, osteoclast maturation, and osteoclast-mediated bone resorption in a culture model of bone matrix. Conversely, knocking down Ddr2 through RNA interference accelerated osteoclast differentiation and bone resorption in mice. Further, we identified the co-receptor Neuropilin-1 (Nrp1) as a DDR2-interacting protein. DDR2 facilitated the binding of Nrp1 and the co-receptor PlexinA1 by forming a DDR2-Nrp1-PlexinA1 complex, which blocked PlexinA1-mediated stimulation of osteoclastogenesis. DDR2 prevented PlexinA1 from interacting with the receptor TREM2 and the adaptor DAP12. Moreover, knocking down Nrp1 rescued the expression of osteoclastic markers observed in DDR2-overexpressing cells, whereas ectopic expression of Nrp1 in DDR2-silenced cells inhibited the induction of osteoclastogenesis. Nrp1 enhanced the function of DDR2 in promoting osteoblast differentiation and bone formation in mice. In an ovariectomized mouse model of osteoporosis, adenovirus-mediated delivery of DDR2 to the femur bone alleviated osteopenic phenotypes. Our results revealed that DDR2 functions as an inhibitor of osteoclastogenesis, as well as a promoter of osteoblastogenesis, suggesting that enhancing DDR2 may be therapeutic for patients with osteoporosis.

Exploring the Cellular and Molecular Mechanism of Discoidin Domain Receptors (DDR1 and DDR2) in Bone Formation, Regeneration, and Its Associated Disease Conditions

An Essential Role of Discoidin Domain Receptor 2 (DDR2) in Osteoblast Differentiation and Chondrocyte Maturation Via Modulation of Runx2 Activation

Discoidin domain receptors orchestrate cancer progression: A focus on cancer therapies

Discoidin domain receptors (DDRs): Potential implications in periodontitis

Targeting Discoidin Domain Receptor 2 for the Development of Disease-Modifying Osteoarthritis Drugs

Recent Advances in the Role of Discoidin Domain Receptor Tyrosine Kinase 1 and Discoidin Domain Receptor Tyrosine Kinase 2 in Breast and Ovarian Cancer

DDR2 (discoidin domain receptor 2) suppresses osteoclastogenesis and is a potential therapeutic target in osteoporosis

Complex roles of discoidin domain receptor tyrosine kinases in cancer

Ablation of Discoidin Domain Receptor 1 Provokes an Osteopenic Phenotype by Regulating Osteoblast/Osteocyte Autophagy and Apoptosis

Small molecule discoidin domain receptor kinase inhibitors and potential medical applications.

Discoidin Domain Receptor 1 As a Potent Therapeutic Target in Solid Tumors

Expression, Purification and Functional Identification of Extracellular Part of Discoidin Domain Receptor 2

A network map of discoidin domain receptor 1(DDR1)-mediated signaling in pathological conditions

Structure of the Discoidin Domain Receptor 1 Extracellular Region Bound to an Inhibitory Fab Fragment Reveals Features Important for Signaling

Research progress of DDR1 inhibitors in the treatment of multiple human diseases

DDR1-targeted therapies: current limitations and future potential

The Role of DDR1 in Cancer and the Progress of Its Selective Inhibitors

Expression of Discoidin Domain Receptor 2 (DDR2) Extracellular Domain in Pichia Pastoris and Functional Analysis in Synovial Fibroblasts and NIT3T3 Cells

Discoidin Domain Receptor 1 (DDR1): an Emerged Novel Mechanosensor

Interaction of discoidin domain receptor 1 isoform b (DDR1b) with collagen activates p38 mitogen‐activated protein kinase and promotes differentiation of macrophages

Cloning, Expression and Functional Analysis of the Extracellular Part of Discoidin Domain Receptor 2